Buy

Cohance Lifesciences’ (Cohance) Q4FY25 pro forma financial performance was below our expectation. Momentum across its pharma CDMO (+31% YoY) was strong, while specialty chemical CDMO business growth (+75%) is beginning to recover.

Britannia delivered a strong quarter, with growth in the topline, on the back of an expanded network, effective cost management and margin preservation despite significant input inflation. The management remained vigilant on input costs and competition, executing a disciplined return on investment-focused strategy for organic as well as inorganic growth. In fact, although input costs remain a concern, the company's disciplined approach, commitment towards sustainability as well as...

Apeejay Surrendra Park Hotels Ltd.'s (ASPHL) Q4FY25 result was broadly in-line with our estimates on net sales and EBITDA front, while net profitability disappointed. The company witnessed an increase of 13% YoY in both ARR at 8,758, and RevPAR at 8,074, while occupancy stood at 92%. The management reiterated high teens growth for FY26E, which is encouraging. ASPHL intends to double its key count to about 5400 keys in the next 5 years including 1,011 keys of its own. In Q4FY25 ASPHL signed a binding MoU for the acquisition 60 service apartment under Zillion Hotels and Resorts at Juhu, Mumbai. Further, the...

Cummins India (KKC) delivered healthy performance in Q4FY25 which were in tune with our estimates. Revenue for the quarter was higher by 7% YoY and lower by 20% QoQ. The key positive of the management commentary was demand continuing to remain strong and also being broad based across key infrastructure verticals like residential real estate, commercial realty and data centers. Another key positive was of Gross margins coming in at 37.5% for the quarter. This is a result of the management's assiduous efforts in reducing direct material costs, optimizing product mix and suitable pricing. Guidance is of...

We maintain our BUY rating on the stock.

We maintain our BUY recommendation on the stock.

LIC saw VNB/EV grow 4.5%/6.8% YoY in FY25. Strategic initiatives have tracked well consistently in terms of pushing product mix towards non-participating (28% of individual APE in FY25 vs. 18%/9% in FY24/FY23) and revision in pricing/product strategy to maximise value for all stakeholders with changes like hike in surrender value.

Vinati Organics reported a strong Q4FY25 with revenue up 17.5% y-o-y, operating profit growth of 20.4% and net profit increase of 18.1% y-o-y.

Sumitomo Chemical (Sumitomo) reported subdued 4Q numbers below our and consensus estimates with flat revenue growth while EBITDA and PAT declined by 15% and 9% y/y respectively.

More volumes pushed up Stylam’s Q4 FY25 revenue 10.6% y/y to ~Rs2.7bn, though blended realisation were soft. High input costs and product-mix changes pulled gross profit down 7.1% y/y to Rs1.1bn.

realization and flat gas realization combined with growth in oil sales, sales grew by 2.8% QoQ. However, higher other expenditure led to EBITDA of Rs19.8bn, -7% QoQ (PLe Rs20.9bn, consensus Rs22.7bn). Lower than expected...

Rs650mn losses in FY25 from its clinics and NHIC business. Q4FY25, 5% above our estimates aided by higher profitability across Cayman 28% QoQ. India business reported healthy EBITDA adjusted for NHIC losses, up 18% YoY. The management reiterated its aggressive capex plan and commitment towards growing throughput over the next 3-4 years through...

We maintain our BUY rating on the stock.

We maintain our BUY recommendation on Aurobindo Pharma with a TP of Rs 1,500/share.

Dismal Q4 on continued market share loss in bathware and muted performance of the consumer appliance business

APE and VNB growth slows, expected to normalise going ahead

Standalone revenues stood at Rs. 687 crore, up 2.3% q-o-q/13% y-o-y in line with our estimates of Rs 692 crore. Recruitment business continued to grow, whereas non-recruitment businesses also continued to grow with cash profitability.

Standalone revenue grew by 32% y-o-y to Rs. 8,926 crore while EBITDA was at Rs. 221 crore fell 58% y-o-y. In Q4 Cellulosic Fibre revenue grew by 8% y-o-y While EBITDA de-grew by 36% y-o-y due to increased key input costs.

Colgate’s Q4FY25 performance was muted owing to soft demand in urban markets and heightened competitive intensity. Standalone revenues declined by 1.8% y-o-y to Rs. 1,463 crore, missing our expectation of Rs. 1,520 crore, with toothpaste volumes flat y-o-y.

The company reported revenue of ?4,925 Million for the quarter ended March 2025, marking an 16.1% year-on-year increase from ?4,241 Million in the same quarter last year, and a growth of 25.5% rise on a sequential basis.